tiprankstipranks
Faron Pharmaceuticals Oy (GB:FARN)
LSE:FARN
UK Market
FARN
Faron Pharmaceuticals Oy
RESEARCH TOOLSreports

Faron Pharmaceuticals Oy (FARN) Stock News & Sentiment

70 Followers
Faron Pharmaceuticals Calls AGM, Seeks Capital-Raising Mandate and Strengthens Board
Premium
Company Announcements
Faron Pharmaceuticals Calls AGM, Seeks Capital-Raising Mandate and Strengthens Board
8h ago
Faron registers new shares as major equity offering nears completion
Premium
Company Announcements
Faron registers new shares as major equity offering nears completion
9h ago
Faron raises EUR 40.1 million in rights issue to advance cancer drug bexmarilimab
Premium
Company Announcements
Faron raises EUR 40.1 million in rights issue to advance cancer drug bexmarilimab
1d ago
Faron raises €40 million in oversubscribed rights issue to drive bexmarilimab trials
Premium
Company Announcements
Faron raises €40 million in oversubscribed rights issue to drive bexmarilimab trials
2d ago
Faron Chair Buys Shares in Rights Issue to Back Cancer Immunotherapy Drive
Premium
Company Announcements
Faron Chair Buys Shares in Rights Issue to Back Cancer Immunotherapy Drive
11d ago
Faron bolsters late-stage push with new CTO for lead cancer immunotherapy
Premium
Company Announcements
Faron bolsters late-stage push with new CTO for lead cancer immunotherapy
16d ago
Buy Rating Reiterated on Faron: De-Risked Bexmarilimab Strategy in High-Risk MDS and Upside from Solid Tumor Expansion
Premium
Ratings
Buy Rating Reiterated on Faron: De-Risked Bexmarilimab Strategy in High-Risk MDS and Upside from Solid Tumor Expansion
22d ago
More GB:FARN News >

FARN News on the Web

Faron raises EUR 40.1 million in rights issue to advance cancer drug bexmarilimab
TipRanks News
Bullish
Faron raises €40 million in oversubscribed rights issue to drive bexmarilimab trials
TipRanks News
Bullish
Faron Chair Buys Shares in Rights Issue to Back Cancer Immunotherapy Drive
TipRanks News
Bullish
Faron bolsters late-stage push with new CTO for lead cancer immunotherapy
TipRanks News
Bullish
Faron Pharmaceuticals appoints new CTO to advance cancer immunotherapy into late-stage trials
Proactive Investors
Bullish
Buy Rating Reiterated on Faron: De-Risked Bexmarilimab Strategy in High-Risk MDS and Upside from Solid Tumor Expansion
TipRanks News
Bullish
Faron CEO Boosts Stake in Rights Issue, Underscoring Confidence in Cancer Immunotherapy Pipeline
TipRanks News
Bullish
Faron Senior Advisor Boosts Stake as Cancer Immunotherapy Trials Advance
TipRanks News
Neutral

News Score - Last 7 Days

Positive
GB:FARN
Sector Average
Media Buzz
This Week2 articles
Weekly Average2.5 articles
News Sentiment
This Week100%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is GB:FARN’s Media Buzz Sentiment?
2 articles about GB:FARN were published this week. In an average week, 2.5 articles are published.
    What is GB:FARN’s weekly average amount of articles?
    In an average week, 2.5 articles about GB:FARN are published.
      What is GB:FARN’s News Sentiment?
      100% of articles about GB:FARN were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        NBIXNeurocrine
        STAAStaar Surgical
        AORTArtivion
        OWLTOwlet
        HUMHumana
        Showing the stocks with the most bullish news sentiment over the past week